Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug metabolism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    625 result(s) found for: Drug metabolism. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-001513-13 Sponsor Protocol Number: LAL-CL04 Start Date*: 2011-10-24
    Sponsor Name:Synageva Biopharma Corp.
    Full Title: AN OPEN LABEL MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SBC-102 IN ADULT SUBJECTS WITH LIVER DYSFUNCTION DUE TO LYSOSOMAL ACID LIPASE DEFICIENCY WH...
    Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    14.1 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    14.1 10010331 - Congenital, familial and genetic disorders 10024579 Lysosomal storage disorders HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-002880-42 Sponsor Protocol Number: LAL-CL05 Start Date*: 2011-12-05
    Sponsor Name:Synageva Biopharma Corp.
    Full Title: An Open Label Multicenter Extension Study to Evaluate the Long-Term Efficacy and Safety of SBC 102 in Children with Lysosomal Acid Lipase Deficiency Who Previously Received Treatment with SBC-102
    Medical condition: Growth failure in children due to lysosomal acid lipase deficiency (Wolman disease).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    14.0 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    14.0 10010331 - Congenital, familial and genetic disorders 10024579 Lysosomal storage disorders HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000032-28 Sponsor Protocol Number: LAL-CL03 Start Date*: 2011-04-18
    Sponsor Name:Synageva Biopharma Corp.
    Full Title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal ...
    Medical condition: Growth failure in children due to lysosomal acid lipase deficiency (Wolman disease).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    14.1 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    14.1 10010331 - Congenital, familial and genetic disorders 10024579 Lysosomal storage disorders HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Prematurely Ended) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003406-10 Sponsor Protocol Number: BC21144 Start Date*: 2007-12-13
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Ar...
    Medical condition: Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013317 Lipid metabolism disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024068-16 Sponsor Protocol Number: LAL-CL01 Start Date*: 2011-03-08
    Sponsor Name:Synageva Biopharma Corp.
    Full Title: An open label multicenter study to evaluate the safety, tolerability and pharmacokinetics of SBC-102 in adult patients with liver dysfunction due to lysosomal acid lipase deficiency.
    Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    14.0 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    14.0 10010331 - Congenital, familial and genetic disorders 10024579 Lysosomal storage disorders HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003989-27 Sponsor Protocol Number: PROLONGSTEM Start Date*: Information not available in EudraCT
    Sponsor Name:Promethera Therapeutics
    Full Title: PROLONGSTEM: HepaStem Long-Term Safety Registry Registry for patients who have been administered HepaStem
    Medical condition: This study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HALPC during a previous interventional clinical study conducted by...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10021601 Inborn error of metabolism NOS LLT
    20.0 100000004871 10008954 Chronic liver disease and cirrhosis LLT
    20.1 100000004871 10049844 Acute liver failure LLT
    21.1 200000003094 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003014-22 Sponsor Protocol Number: Thalamus_V3 Start Date*: 2018-06-25
    Sponsor Name:Medical University of Vienna
    Full Title: The role of leptin in regulating hepatic lipid metabolism in humans
    Medical condition: lipodystrophy patients, patients after liver transplantation and healthy controls
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000152-34 Sponsor Protocol Number: 2012-000152-34 Start Date*: 2012-02-09
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: evaluation of the effect of treatment with DPP-4 inhibitor on endothelial function versus sulphonylurea on markers of oxidative stress and inflammation and platelet function in patients with diabet...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005497-28 Sponsor Protocol Number: PedMic Start Date*: 2013-09-27
    Sponsor Name:Erasmus MC - Sophia
    Full Title: Pediatric Microdosing: elucidating age-related changes in oral absorption
    Medical condition: Age-related changes in intestinal drug metabolism in children
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022075-66 Sponsor Protocol Number: 10/CMC/4767E Start Date*: 2010-12-16
    Sponsor Name:Cardif and Vale University Local Health Board
    Full Title: A Single Centre Physiological Study of Glucose Metabolism Before and After Tacrolimus Withdrawal For Deteriorating Kidney Function In Renal Transplant Recipients
    Medical condition: Alterations in glucose metabolism secondary to tacrolimus (Prograf), a calcineurin inhibitor, after kidney transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005491-20 Sponsor Protocol Number: 20151205 Start Date*: 2016-08-29
    Sponsor Name:Actavis Hungary Gyógyszermarketing és Kereskedelmi Korlátolt Felelősségű Társaság
    Full Title: The effect of pancreatic enzyme replacement therapy on glucose metabolism, nutritional parameters, incretin response and beta-cell function in patients with diabetes mellitus and exocrine pancreati...
    Medical condition: To study the patients with diabetes mellitus (type 1, 2 and 3c) and exocrine pancreatic insufficiency.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001336-22 Sponsor Protocol Number: AX-PC-201 Start Date*: 2004-11-03
    Sponsor Name:Axonyx Inc.
    Full Title: Effect of Phenserine Treatment on Amyloid in Brains of Patients with Mild Probable Alzheimer’s Disease as studied by Positron Emission Tomography (PET). A Randomised, three Months Double-Blind, Pla...
    Medical condition: Alzheimer’s Disease (AD) is the most common disease leading to dementia and it affects approximately 4 to 8% of the population aged above 65 years. The disease incidence is closely correlated with ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003755-64 Sponsor Protocol Number: DiAPREV/2014 Start Date*: 2014-11-13
    Sponsor Name:Helena Elding Larsson
    Full Title: A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® in combination with Vitamin D on the progression to type 1 diabetes in children with multip...
    Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001655-41 Sponsor Protocol Number: 35RC19_8877_DIPLOID Start Date*: 2020-09-15
    Sponsor Name:CHU de Rennes
    Full Title: P-glypoprotein inhibition effect on the pharmacokinetics of two tacrolimus formulations: prolonged and extended-release
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000075-27 Sponsor Protocol Number: HPN-100-021 Start Date*: 2016-03-07
    Sponsor Name:Horizon Therapeutics, LLC
    Full Title: A Randomised, Controlled, Open-Label Parallel Arm Study of the Safety, Pharmacokinetics and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate [GPB]) Oral Liquid and Sodium Phenylbutyrate (NaPBA)...
    Medical condition: Urea Cycle Disorders (UCDs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161833 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005473-36 Sponsor Protocol Number: Dezember2014Version2 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects
    Medical condition: familial hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000534-20 Sponsor Protocol Number: THAM05 Start Date*: 2005-03-15
    Sponsor Name:Addenbrooke's Hospital NHS Foundation Trust
    Full Title: Influence of brain tissue pH regulation on cerebral oxygenation and metabolism in patients with severe traumatic brain injury.
    Medical condition: Severe traumatic brain injury
    Disease:
    Population Age: Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004946-13 Sponsor Protocol Number: Taglumet Start Date*: 2020-08-20
    Sponsor Name:Univeristy Hospital Tuebingen
    Full Title: Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile
    Medical condition: stable adult kidney transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004815-22 Sponsor Protocol Number: INDICES/WP2/01 Start Date*: 2012-01-24
    Sponsor Name:Research Institute of Biological Psychiatry Sct. Hans
    Full Title: Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1)
    Medical condition: Healthy volunteers with special genotypes
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10053349 Pharmacokinetic study LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003598-33 Sponsor Protocol Number: LJ401-HH01 Start Date*: 2018-04-03
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Phase 2, Multi-center, Randomized, Placebo-controlled, Single-blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:18:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA